Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Jan-Feb;10(1):23-33.
doi: 10.1370/afm.1316.

Depression treatment in patients with general medical conditions: results from the CO-MED trial

David W Morris  1 , Nitin Budhwar, Mustafa Husain, Stephen R Wisniewski, Benji T Kurian, James F Luther, Kevin Kerber, A John Rush, Madhukar H Trivedi
Affiliations
Randomized Controlled Trial

Depression treatment in patients with general medical conditions: results from the CO-MED trial

David W Morris et al. Ann Fam Med. 2012 Jan-Feb.

Abstract

Purpose: We studied the effect of 3 antidepressant treatments on outcomes (depressive severity, medication tolerability, and psychosocial functioning) in depressed patients having comorbid general medical conditions in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial.

Methods: Adult outpatients who had chronic and/or recurrent major depressive disorder (MDD) with and without general medical conditions were randomly assigned in 1:1:1 ratio to 28 weeks of single-blind, placebo-controlled antidepressant treatment with (1) escitalopram plus placebo, (2) bupropion-SR plus escitalopram, or (3) venlafaxine-XR plus mirtazapine. At weeks 12 and 28, we compared response and tolerability between participants with 0, 1, 2, and 3 or more general medical conditions.

Results: Of the 665 evaluable patients, 49.5% reported having no treated general medical conditions, 23.8% reported having 1, 14.8% reported having 2, and 11.9% reported having at least 3. We found only minimal differences in antidepressant treatment response between these groups having different numbers of conditions; patients with 3 or more conditions reported higher rates of impairment in social and occupational functioning at week 12 but not at week 28. Additionally, we found no significant differences between the 3 antidepressant treatments across these groups.

Conclusions: Patients with general medical conditions can be safely and effectively treated for MDD with antidepressants with no additional adverse effect or tolerability burden relative to their counterparts without such conditions. Combination therapy is not associated with an increased treatment response beyond that found with traditional monotherapy in patients with MDD, regardless of the presence and number of general medical conditions.

Trial registration: ClinicalTrials.gov NCT00590863.

PubMed Disclaimer

Comment in

References

    1. Depression Guideline Panel Clinical Practice Guideline, Number 5: Depression in Primary Care, Volume 1: Detection and Diagnosis. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1993. AHCPR publication 93–0550
    1. Cornwall PL, Scott J. Partial remission in depressive disorders. Acta Psychiatr Scand. 1997;95(4):265–271 - PubMed
    1. Keller MB, Klein DN, Hirschfeld RMA, et al. Results of the DSM-IV mood disorders field trial. Am J Psychiatry. 1995;152(6):843–849 - PubMed
    1. Depression Guideline Panel Clinical Practice Guideline, Number 5: Depression in Primary Care: Volume 2: Treatment of Major Depression. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1993. AHCPR publication 93–0551
    1. Lin EH, Katon WJ, VonKorff M, et al. Relapse of depression in primary care. Rate and clinical predictors. Arch Fam Med. 1998;7(5): 443–449 - PubMed

Publication types

MeSH terms

Associated data